Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 4.01% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2025-05-13
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2024-03-31 was 4.01%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2015-09-30 was 0.69%, a 0.00% change year-over-year.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2014-09-30 was 0.69%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 4.01%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2015 was 0.69%, a 0.00% change from fiscal 2014.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2014 was 0.69%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2024-12-31 | 4.01% 10-K · filed 2025-03-31 | |||
| 2024-09-30 | 4.01% 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | 4.01% 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | 4.01% 10-Q · filed 2025-05-13 | |||
| 2015-12-31 | 0.69% 10-Q · filed 2016-03-11 | |||
| 2015-09-30 | 0.69% 10-Q · filed 2015-11-13 | |||
| 2015-06-30 | 0.69% 10-K · filed 2015-09-25 | |||
| 2015-03-31 | 0.69% 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | 0.69% 10-Q · filed 2015-02-06 | |||
| 2014-09-30 | 0.69% 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | 0.69% 10-K · filed 2014-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |